8-KLeadership ChangesExhibits & Filings

AMGEN INC 8-K Report, Executive Changes (Dec 14, 2023)

Filed December 14, 2023For Securities:AMGN

Summary

Amgen Inc. (AMGN) announced significant leadership changes within its Research and Development (R&D) and technology functions, effective December 18, 2023. Dr. David M. Reese is transitioning from his role as Executive Vice President, Research and Development, to a newly created position as Executive Vice President and Chief Technology Officer. In this new capacity, Dr. Reese will focus on leveraging technology and artificial intelligence (AI) to enhance Amgen's operations across the board. Concurrently, Amgen has appointed Dr. James Bradner as its new Executive Vice President, Research and Development, and Chief Scientific Officer. Dr. Bradner brings substantial experience from his previous role as President of the Novartis Institutes for BioMedical Research and membership in Novartis's Executive Committee. These strategic appointments signal Amgen's commitment to innovation, both in its core R&D endeavors and in the adoption of advanced technologies like AI to drive future growth and efficiency.

Key Highlights

  • 1Dr. David M. Reese appointed Executive Vice President and Chief Technology Officer, a new role focused on AI and technology acceleration.
  • 2Dr. James Bradner hired as Executive Vice President, Research and Development, and Chief Scientific Officer.
  • 3Dr. Bradner's prior experience includes serving as President of Novartis Institutes for BioMedical Research.
  • 4These leadership changes are effective December 18, 2023.
  • 5Both Dr. Reese and Dr. Bradner will report directly to CEO Robert A. Bradway.
  • 6The appointments underscore a strategic focus on integrating technology and AI into R&D and broader company operations.

Frequently Asked Questions

The creation of the Chief Technology Officer role and the appointment of Dr. David M. Reese to it highlight Amgen's strategic focus on integrating advanced technologies, particularly artificial intelligence (AI), across all aspects of the company. This move is expected to drive innovation, improve efficiency, and accelerate drug discovery and development processes.

Dr. James Bradner brings extensive experience in pharmaceutical research and development, having previously served as President of the Novartis Institutes for BioMedical Research and a member of Novartis's Executive Committee. This leadership background is expected to strengthen Amgen's core R&D capabilities and scientific direction.

The appointments of Dr. David M. Reese to Chief Technology Officer and Dr. James Bradner to Executive Vice President, Research and Development, and Chief Scientific Officer are both effective as of December 18, 2023.

Both Dr. Reese and Dr. Bradner will report directly to Amgen's Chairman and Chief Executive Officer, Robert A. Bradway, indicating the strategic importance of these roles to the company's leadership.